Acrux Ltd - Company Profile
Powered by 
All the data and insights you need on Acrux Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Acrux Ltd Strategy Report
- Understand Acrux Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Acrux Ltd (Acrux) is a pharmaceutical company that develops and commercializes generic and specialty topical pharmaceuticals. Its products are used for the treatment of fungal infection, endogenous testosterone and anaesthesia. The company's products include testosterone topical solution and estradiol MDTS. Testosterone Topical Solution for treatment of adult males with no testosterone or low testosterone and Estradiol for the treatment of moderate to severe hot flushes. The company's major pipeline products include Jublia for treatment of fungal infection of the nail and EMLA cream for the treatment of topical anaesthetics. Acrux is headquartered in Melbourne, Victoria, Australia.
Headquarters
Australia
Address
103-113 Stanley St, West Melbourne, Victoria, 3003
Website
www.acrux.com.au
Telephone
61 3 83790100
No of Employees
43
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ACR (ASX)
Revenue (2022)
$8.3M
133.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
92.2%
(2022 vs 2021)
Market Cap*
$11.7M
Net Profit Margin (2022)
XYZ
96.7%
(2022 vs 2021)
* As of and is in US$
Acrux Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Jublia: | Axiron |
| Fungal Infection of the Nail | Jublia |
| Testosterone Solution: | Evamist |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In June, the company received the US FDA approval for ANDA, a generic version of Aczone Gel, 5%. |
| 2022 | Others | In December, the company terminated the agreement with Amring Pharmaceuticals Inc. for the development and commercialization of a generic topical product for the US market. |
| 2020 | Contracts/Agreements | In October, the company entered into an agreement with Dash Pharmaceuticals for marketing, sales and distribution of its products in its pipeline. |
Competitor Comparison
| Key Parameters | Acrux Ltd | Pfizer Inc | Teva Pharmaceutical Industries Ltd | Allergan Finance LLC | Amneal Pharma Australia Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | United States of America | Israel | United States of America | Australia |
| City | Melbourne | New York | Tel Aviv | Parsippany | Melbourne |
| State/Province | Victoria | New York | Tel Aviv | New Jersey | Victoria |
| No. of Employees | 43 | 88,000 | 35,001 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Kotsanis | Director; Managing Director; Chief Executive Officer | Executive Board | 2014 | - |
| Joanna Johnson | Chief Financial Officer; Secretary | Senior Management | 2021 | - |
| Ross Dobinson | Chairman | Non Executive Board | 2006 | - |
| Mark Hyman | Director - Project and Technical Development | Senior Management | 2020 | - |
| Felicia Colagrande | Director - Product Development and Technical Affairs | Senior Management | 2015 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer